Results 171 to 180 of about 188,451 (293)

Supplementary Video 2 from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia

, 2023
Ahmet Tunceroglu, Michiyuki Matsuda, Raymond B. Birge   +2 more
openalex   +1 more source

Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia [PDF]

, 2020
Philip T. Sobash, Achuta Kumar Guddati, Vamsi Kota   +2 more
openalex   +1 more source

Chronic myelogenous leukemia, version 1.2015.

The Journal of the National Comprehensive Cancer Network, 2014
S. O'brien, J. Radich, C. Abboud, M. Akhtari, J. Altman, E. Berman, P. Curtin, D. DeAngelo, M. Deininger, S. Devine, A. Fathi, J. Gotlib, M. Jagasia, P. Kropf, J. Moore, A. Pallera, Vishnu V Reddy, N. Shah, B. Smith, David S. Snyder, M. Wetzler, K. Gregory, Hema M Sundar   +22 more
semanticscholar   +1 more source

Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia. [PDF]

Leuk Res Rep
Ensafi Talemi F, Ghafouri-Fard S.
europepmc   +1 more source

Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia [PDF]

, 1994
William R. Drobyski, RC Ash, JT Casper, T McAuliffe, MM Horowitz, C. Lawton, C Keever, LA Baxter-Lowe, Bruce M. Camitta, F Garbrecht   +9 more
openalex   +1 more source

Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells.

Cancer Letters, 2014
C. Corrado, S. Raimondo, L. Saieva, A. Flugy, G. De Leo, R. Alessandro   +5 more
semanticscholar   +1 more source

Pathogenesis of chronic myelogenous leukemia

Haematologica, 1994
G Bergamaschi, V Rosti
doaj   +1 more source

Research on the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia. [PDF]

Discov Oncol
Feng X, Qin Y, Feng Y, Zhuo Y.
europepmc   +1 more source

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. [PDF]

Front Oncol, 2022
Yoshifuji K, Sasaki K.
europepmc   +1 more source

Uncommon phenotypes of <i>BCR::ABL1</i>-positive chronic myelogenous leukemia. [PDF]

Haematologica
Jajosky AN, Lichtman MA.
europepmc   +1 more source